Diaceutics (DXRX) RNS Announcements

Add to Alert list
Date Time Source Announcement
29 Dec 2023 01:18 PM
RNS
PDMR Shareholding/Share Incentive Plan
30 Nov 2023 12:59 PM
RNS
PDMR Shareholding/Share Incentive Plan and TVR
30 Nov 2023 07:00 AM
RNS
Diaceutics to attend Stifel Conference in NYC
21 Nov 2023 11:13 AM
RNS
Notification of Major Holdings
31 Oct 2023 12:38 PM
RNS
PDMR Shareholding/SIP & Total Voting Rights
11 Oct 2023 01:47 PM
RNS
PDMR Shareholding/Share Incentive Plan and TVR
02 Oct 2023 03:59 PM
RNS
Block Listing Application to AIM
29 Sep 2023 11:19 AM
RNS
Holding(s) in Company
29 Sep 2023 11:19 AM
RNS
Holding(s) in Company
26 Sep 2023 07:00 AM
RNS
Diaceutics PLC – Half Year Results
26 Sep 2023 07:00 AM
RNS
Diaceutics PLC - Planned CEO Transition
21 Sep 2023 02:37 PM
RNS
Diaceutics PLC – Directorate Changes
07 Sep 2023 07:00 AM
RNS
Attending 10th Annual HealthTech Investment Forum
05 Sep 2023 07:00 AM
RNS
Notice of Interim Results and Presentations
30 Aug 2023 02:56 PM
RNS
PDMR Shareholding/Share Incentive Plan
29 Aug 2023 07:00 AM
RNS
Diaceutics launches daily alerts for DXRX platform
04 Aug 2023 07:00 AM
RNS
Canaccord Genuity 43rd Annual Growth Conference
31 Jul 2023 03:19 PM
RNS
PDMR Shareholding/Share Incentive Plan
25 Jul 2023 07:00 AM
RNS
Trading Update and Notice of Results
29 Jun 2023 12:07 PM
RNS
PDMR Shareholding/Share Incentive Plan
06 Jun 2023 07:00 AM
RNS
Purchase and Sale of Shares and PDMR Shareholdings
05 Jun 2023 07:00 AM
RNS
USD 10.1 million multi-year enterprise engagement
31 May 2023 05:13 PM
RNS
PDMR Shareholding/Share Incentive Plan
19 May 2023 10:16 AM
RNS
Issue of Share Options/PDMR Shareholdings
18 May 2023 11:46 AM
RNS
Results of Annual General Meeting
11 May 2023 06:22 PM
RNS
PDMR Shareholdings
04 May 2023 10:34 AM
RNS
PDMR shareholdings
26 Apr 2023 05:03 PM
RNS
PDMR Shareholding
25 Apr 2023 05:45 PM
RNS
Notice of AGM and Posting of Annual Report
17 Apr 2023 07:00 AM
RNS
Final Results
03 Apr 2023 02:43 PM
RNS
PDMR Shareholding / Share Incentive Plan
20 Mar 2023 07:00 AM
RNS
Notice of Results and Presentations
13 Mar 2023 10:12 AM
RNS
Further update regarding Silicon Valley Bank
13 Mar 2023 07:00 AM
RNS
Update regarding Silicon Valley Bank
01 Mar 2023 01:57 PM
RNS
PDMR Shareholding/Share Incentive Plan
30 Jan 2023 05:11 PM
RNS
PDMR Shareholding/Share Incentive Plan
26 Jan 2023 07:00 AM
RNS
USD 7m enterprise engagements for data services
26 Jan 2023 07:00 AM
RNS
Trading Statement and Strategy Update
03 Jan 2023 07:00 AM
RNS
PDMR Shareholding/Share Incentive Plan
29 Nov 2022 07:00 AM
RNS
Change of Auditor
29 Nov 2022 07:00 AM
RNS
PDMR Shareholding/Share Incentive Plan
01 Nov 2022 07:00 AM
RNS
Sub-optimal testing impacts on cancer patients
31 Oct 2022 02:20 PM
RNS
PDMR Shareholding/Share Incentive Plan
05 Oct 2022 05:03 PM
RNS
PDMR Shareholding/Share Incentive Plan
05 Oct 2022 07:00 AM
RNS
Purchase of Shares and PDMR Shareholding
27 Sep 2022 07:00 AM
RNS
Half-year Report
12 Sep 2022 12:38 PM
RNS
PDMR Shareholding/Share Incentive Plan
08 Sep 2022 07:00 AM
RNS
Notice of Results and Presentations
08 Aug 2022 07:00 AM
RNS
PDMR Shareholding/Share Incentive Plan
26 Jul 2022 07:00 AM
RNS
Trading Update and Notice of Results

Diaceutics PLC, a global leader in the field of precision medicine, holds a significant position on the London Stock Exchange (LSE). As part of the dynamic financial ecosystem facilitated by the London Stock Exchange Group (LSEG), Diaceutics PLC contributes to the global financial landscape.

The Diaceutics share price and DXRX share price are key indicators of the company's market performance. These metrics are closely monitored by investors to assess the company's financial health and make informed investment decisions.

Founded in 2005, Diaceutics PLC is headquartered in Belfast, United Kingdom. The company has been a pioneer in the field of diagnostic testing, collating large amounts of laboratory, patient, claims, and payor data which it uses to deliver diagnostic testing strategies to its clients. Over the years, Diaceutics PLC has amassed a set of data from over 52,515 laboratories, showing disease volumes and 481 million de-identified patient records globally in 53 countries. This data collection has allowed the company to accumulate a proprietary database of laboratory capabilities across the industry.

Diaceutics PLC provides services to 39 global pharmaceutical companies and is focused on optimising its clients’ strategies for the development and launch of precision medicines. Precision medicines are a class of drug tailored to individual patient groups dependent on molecular or genetic factors of the individual. Today, they are used for treatment in oncology as well as other disease areas such as multiple sclerosis and rheumatoid arthritis.

Being listed on the LSE, Diaceutics PLC is part of the vibrant financial ecosystem facilitated by the London Stock Exchange Group (LSEG). LSEG, a leading global financial markets infrastructure and data provider, plays a crucial role in supporting the financial stability and growth of communities and economies globally.

In conclusion, Diaceutics PLC, with its strategic focus on precision medicine and its status as a company listed on the LSE, represents a noteworthy entity in the financial markets landscape facilitated by LSEG. Its share price, referred to as both Diaceutics share price and DXRX share price, are key considerations for investors, reflecting the company's market performance. As part of the vibrant LSEG ecosystem, Diaceutics PLC contributes to the broader financial markets infrastructure, underscoring its significance in the global financial community.

UK 100

Latest directors dealings